| Customization: | Available |
|---|---|
| CAS No.: | High Purity |
| Formula: | C188h293n53o44s |
|
Still deciding? Get samples of US$ 15/vial
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
PNC-27 is a synthetic anti-cancer peptide that binds HDM-2 and thus prevents its interaction with the p53 tumor suppressor protein. Studies show that it selectively kills cancer cells by causing membranolysis (destruction of the cell membrane).
PNC-27 is a new synthetic anti-cancer peptide containing an active fragment and an auxiliary part of the cell-penetrating peptide, which ensures the delivery of the drug into the cell. Cytotoxicity of PNC-27 to cancer cells does not depend on p53 and is due to the ability to bind mHDM2, leading to the formation of a transmembrane pore and necrobiosis of cancer cells without affecting normal cells. PNC-27 has been studied in vitro and in vivo experiments and has shown efficacy against many types of cancer: chemotherapy-resistant human ovarian cancer cell lines, leukemia, and breast carcinoma. PNC-27 can kill paclit axel survivors and improve its antitumor effect. Nanoparticles with PNC-27 can be used for early cancer detection. This peptide appears to be a potentially potent and effective anticancer agent.
Proteins and peptides are effectively used in the treatment of various diseases such as cancer, inflammation and some autoimmune disorders. Some drugs cannot achieve a therapeutic effect, so effective drug delivery approaches that increase their effectiveness are urgently needed. Scientists have discovered a number of short peptides that serve as delivery vectors for macromolecules referred to as cell penetrating peptides (CPPs), protein translocation domains, membrane translocation sequences or "Trojan peptides". From a chemical point of view, CPPs are short, positively charged peptides containing 5-30 amino acid residues that can cross the biomembrane and deliver payloads to cells. This peptide chain contains arginine and lysine residues. Recently, CPPs, both natural and synthetic, have attracted much attention due to their high efficacy and low cytotoxicity in vitro and in vivo. These peptides are excellent for rapid drug delivery, are stable under physiological conditions, and are non-immunogenic molecules. In addition, they provide non-invasive, safe and effective drug delivery without disturbing the cellular structure. One example of a biologically active peptide containing a CPP fragment is the anti-cancer peptide PNC-27.
| Items | Specifications |
| Business Type | We are a manufacturer of GMP peptide and provide OEM service. The lid also can be customized |
| Filling amount | The filling amount is 2-5mg extra per bottle. |
| Purity | The purity is above 99% |
| Price | Competitive price |
| Delivery time | The delivery time is stable and short. If you pay before 12 a.m,the goods can be shipped on the same day. |
| Shipping risk | If the package was lost we will resend the goods to you,so you won't suffer a loss if you buy it. |
Zhaobo Bio acquired early mastery of development and manufacturing of peptides, the short chain amino acids linked by peptide bonds that have enabled new generations of small molecule drugs that closely mimic the body's natural pathways.
Now Zhaobo Bio possesses first-class capabilities to manufacture peptides at industrial scale and in full compliance with the strictest Good Manufacturing Practice (GMP) standards.
Upstream peptide synthesis
Zhaobo Bio production plants are endowed with state-of-the-art equipment for solvent supply, peptide synthesis, purification and isolation of active ingredients and intermediates. All equipment and containment is GMP qualified and cleaning validated. Overlapping capacities and sizes of different equipment trains facilitate a smooth scale-up for increases in demand within the product life cycle.
Downstream purification and isolation of peptides
Zhaobo Bio is committed to the systematic expansion and modernization of its purification equipment in order to ensure the efficient production of ever-increasing amounts of bulk peptide pharmaceuticals.
It uses sophisticated methods for large scale purification campaigns such as preparative high performance liquid chromatography (HPLC), ion exchange (IEX), size-exclusion chromatography (SEC), and ultra-filtration (UF/TFF). The equipment in place permits highly efficient or even continuous manufacturing of extremely pure products up to multi-kg quantities per lot.
For preparative HPLC, dynamic axial compression (DAC) stainless steel columns of up to 60 cm diameter both in batch and continuous mode are packed with the appropriate high performance silica separation phase. For low-pressure chromatography columns up to 80 cm diameter are available. Solvent delivery is ensured from eluent tank farms and containers.
The control of microbiological contamination is a prerequisite for API manufacturing. Class D (ISO 8) and C (ISO 7) clean rooms are supplied via HEPA-filtered, temperature and humidity controlled air, down-flow booths are used for minimizing microbial contamination and protecting operators. Highly active pharmaceutical ingredients are handled in integrated safety workbenches or flexible isolators reaching OEB level 4 (1-10 µg/m3).
Predefined physicochemical properties of the API can only be achieved by a carefully controlled isolation process. Besides precipitation and crystallization, lyophilization of intermediates and final API is a standard unit operation. LaixingPharma have multiple lyophilizers in different sizes (up to 300 liters) located in clean rooms.
){kind=link}